Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

The White House is in discussions with the makers of weight loss drugs Wegovy and Zepbound to drastically lower prices, NBC News has learned. The prices could drop from an average price of $1,300 a ...

Drugmaker Eli Lilly said its drug Zepbound led to more weight loss than Novo Nordisk's Wegovy in a head-to-head comparison. Adults taking Zepbound lost 47% more weight on average than those taking ...

Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more ...

U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...

Wegovy and Zepbound are 2 FDA-approved injectables for weight loss. Learn how they compare in benefits, side effects, and more to decide which option suits you best.

Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 ...

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than rival Novo Nordisk’s NVO Wegovy in a first-ever head-to-head obesity study, ...

*Billed as $4.00 plus GST every four weeks. After 24 weeks, price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only.

President Donald Trump has announced a major deal with Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their blockbuster obesity drugs, Zepbound and Wegovy. These GLP-1 treatments, ...

On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this ...